Pelthos Therapeutics PTHS
NYSE PTHS
$17.02 -2.77 (-14.00%)
At close: Oct 23, 2026 · 4:00 PM EDT

Pelthos Therapeutics (PTHS) Gains from Sales and Divestitures (2024)

Updated

Analysis

Pelthos Therapeutics (PTHS) Gains from Sales and Divestitures (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn
10 Pelthos Therapeutics 63.29 Mn -25.10 Mn 11.99 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 363,091.00
API Access

Pelthos Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=PTHS&period=max&api_key=YOUR_API_KEY